Scienture Holdings (SCNX) Q3 2025 earnings summary

Executive summary

• Completed strategic divestitures of legacy subsidiaries to focus on branded and specialty pharmaceuticals, highlighted by the acquisition of Scienture in July 2024.

• Launched SCN-102 (Arbli™), the first FDA-approved ready-to-use oral liquid losartan, in Q3 2025, driving a significant increase in revenue.

• Streamlined operations and reallocated resources to accelerate product development and commercialization in CNS and CVS therapeutic areas.

Financial highlights

• Revenue for Q3 2025 was $590,050, up 810% year-over-year; nine-month revenue reached $600,308, up 618%.

• Gross profit margin for Q3 2025 was 97.39%, compared to 5.99% in Q3 2024; nine-month gross margin was 95.83%.

• Net loss from continuing operations for Q3 2025 was $3,607,361, compared to $3,183,601 in Q3 2024; nine-month net loss was $13,391,931, up from $11,441,764.

• Net income from discontinued operations in the nine months ended September 30, 2024, was $27,670,294, primarily from asset sales.

• Cash at September 30, 2025, was $355,692, with working capital of $(5,930,372).

Outlook and guidance

• Management expects continued investment in R&D and commercialization of pipeline products, with a focus on expanding the CNS and CVS portfolio.

• Additional capital or debt funding will be required to support ongoing operations and future growth.

• Uncertainty remains regarding the ability to meet funding requirements over the next 12 months, raising substantial doubt about going concern status.